Megan Lerner
Overview
Explore the profile of Megan Lerner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
41
Citations
813
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rout M, Malone-Perez M, Park G, Lerner M, Frazer J, Apple B, et al.
Gene
. 2024 Jun;
927:148712.
PMID: 38901535
MFGE8 is a major exosome (EV) protein known to mediate inflammation and atherosclerosis in type 2 diabetes mellitus (T2DM) in animal studies. The pathophysiological role of this protein in obesity,...
2.
Liu B, Kong Y, Alimi O, Kuss M, Tu H, Hu W, et al.
ACS Nano
. 2023 Feb;
17(4):3847-3864.
PMID: 36779870
Postoperative abdominal adhesions are a common problem after surgery and can produce serious complications. Current antiadhesive strategies focus mostly on physical barriers and are unsatisfactory and inefficient. In this study,...
3.
Dang T, Lerner M, Saunders D, Smith N, Gulej R, Zalles M, et al.
Cells
. 2022 May;
11(9).
PMID: 35563787
One of the major obstacles in treating brain cancers, particularly glioblastoma multiforme, is the occurrence of secondary tumor lesions that arise in areas of the brain and are inoperable while...
4.
Rout M, Lerner M, Blackett P, Peyton M, Stavrakis S, Sidorov E, et al.
Am Heart J Plus
. 2022 May;
13.
PMID: 35528316
Background: Hypertriglyceridemia is as an independent risk factor for cardiovascular disease (CVD). Apolipoprotein C-III (ApoC-III) is known to regulate triglyceride (TG) metabolism. However, the causal association between ApoC-III and CVD...
5.
Zalles M, Smith N, Saunders D, Lerner M, Fung K, Battiste J, et al.
J Cell Mol Med
. 2021 Dec;
26(2):570-582.
PMID: 34910361
Glioblastoma (GBM) is the most common primary malignant brain tumour in adults. Despite a multimodal treatment response, survival for GBM patients remains between 12 and 15 months. Anti-ELTD1 antibody therapy...
6.
Towner R, Saunders D, Lerner M, Silasi Mansat R, Yuan T, Barber D, et al.
Am J Nucl Med Mol Imaging
. 2021 Nov;
11(5):363-373.
PMID: 34754607
The blood-brain barrier (BBB) is usually impermeable to several drugs, which hampers treatment of various brain-related diseases/disorders. There have been several approaches to open the BBB, including intracarotid infusion of...
7.
Zalles M, Smith N, Saunders D, Guzman M, Lerner M, Fung K, et al.
Neurooncol Adv
. 2021 Oct;
3(1):vdab132.
PMID: 34704036
Background: Glioblastoma (GBM) is the most aggressive malignant primary brain tumor in adults. These high-grade gliomas undergo unregulated vascular angiogenesis, migration and cell proliferation allowing the tumor cells to evade...
8.
Goyal S, Tanigawa Y, Zhang W, Chai J, Almeida M, Sim X, et al.
Lipids Health Dis
. 2021 Sep;
20(1):113.
PMID: 34548093
Background: Hypertriglyceridemia has emerged as a critical coronary artery disease (CAD) risk factor. Rare loss-of-function (LoF) variants in apolipoprotein C-III have been reported to reduce triglycerides (TG) and are cardioprotective...
9.
Towner R, Gulej R, Zalles M, Saunders D, Smith N, Lerner M, et al.
Geroscience
. 2021 Apr;
43(2):563-578.
PMID: 33846885
Rapamycin (RAPA) is found to have neuro-protective properties in various neuroinflammatory pathologies, including brain aging. With magnetic resonance imaging (MRI) techniques, we investigated the effect of RAPA in a lipopolysaccharide...
10.
Towner R, Smith N, Zalles M, Morris S, Toliver M, Saunders D, et al.
Mult Scler Relat Disord
. 2021 Jan;
49:102786.
PMID: 33517175
Multiple sclerosis (MS) and glioblastoma (GBM) are two distinct diseases that affect the central nervous system (CNS). However, perturbation in CNS vasculature are hallmarks of both diseases. ELTD1 (epidermal growth...